A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Family Heart Foundation unveiled the Cholesterol Connect program for LDL-C Awareness Day, aiming to make it easier for people ...

We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...